Critical Care Cardiology

Cardiogenic Shock

Q: Can cardiogenic shock be present without hypotension?

Yes. Hypoperfusion may occur with preserved blood pressure; assess lactate, urine output, mentation, skin perfusion, renal and hepatic injury, congestion, and hemodynamics rather than relying on blood pressure alone.

Q: What is the preferred initial vasopressor in cardiogenic shock?

Norepinephrine is generally preferred when vasopressor support is needed for inadequate perfusion pressure. Dopamine was associated with more arrhythmias and higher 28-day mortality in the cardiogenic-shock subgroup of SOAP II, while epinephrine caused more refractory shock and lactic acidosis than norepinephrine in a small acute MI-shock trial.

Q: When should a pulmonary artery catheter be used?

Consider early pulmonary artery catheterization for established shock, uncertain phenotype, suspected RV or biventricular failure, persistent hypoperfusion, escalating vasoactive requirements, or tMCS decisions. ACC guidance supports invasive hemodynamic monitoring for diagnosis and management, although randomized outcome benefit remains unproven.

Q: Does routine mechanical circulatory support improve survival?

No. Routine tMCS has not consistently improved survival in randomized studies, and routine extracorporeal life support did not improve outcomes in infarct-related shock. Use devices selectively for refractory hypoperfusion with a clear physiologic objective and exit strategy.

Q: What is the most important definitive intervention in acute MI-associated cardiogenic shock?

Urgent culprit-vessel revascularization is the intervention with established mortality benefit in acute MI-associated cardiogenic shock.

Cardiogenic shock requires immediate recognition of tissue hypoperfusion, rapid identification of a reversible cause, phenotype-directed vasoactive support, serial reassessment, and early escalation or transfer when pharmacologic support cannot preserve end-organ perfusion.

Clinical question: How should clinicians rapidly diagnose, phenotype, stabilize, monitor, and escalate care for adults with cardiogenic shock?

Updated August 21, 20267 minute readCardiology and Critical Care Medicine

What matters in practice

Do not require hypotension to diagnose cardiogenic shock; hypoperfusion may precede or coexist with preserved blood pressure. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine
Obtain ECG, chest radiography, and urgent transthoracic echocardiography or point-of-care ultrasound while measuring lactate, blood gas, CBC, metabolic panel, troponin, and natriuretic peptides. ACCACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology
In acute MI-associated shock, urgent culprit-vessel revascularization is the intervention with established mortality benefit. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock jaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction
Use serial clinical, biochemical, and hemodynamic perfusion markers rather than a blood-pressure target alone; no definitive cardiogenic-shock MAP target has been established. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Norepinephrine is generally favored when vasopressor support is required; dopamine and epinephrine have safety signals including arrhythmia, refractory shock, and lactic acidosis. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Reassess shock severity within hours and at 24 hours. More than one-half of patients initially classified as SCAI B or C deteriorated by 24 hours in a contemporary registry. jaccjaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

First hour

Recognize hypoperfusion and define the immediate phenotype

Treat cardiogenic shock as a dynamic syndrome rather than a single blood-pressure threshold.

Cardiogenic shock is low cardiac output with end-organ hypoperfusion. Hypotension is common but not required: patients may have evolving hypoperfusion with initially preserved arterial pressure. The 2025 ACC concise clinical guidance emphasizes early recognition using congestion findings plus hypoperfusion markers and immediate assessment with laboratory testing, ECG, chest radiography, and echocardiography or point-of-care ultrasound when available. ACC+1ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine

At presentation, determine whether the dominant mechanism is acute MI, acute or acute-on-chronic heart failure, acute valvular or mechanical complication, arrhythmia, myocarditis, right ventricular failure, tamponade, pulmonary embolism, or mixed shock. This distinction changes the urgency of coronary angiography, volume strategy, vasoactive selection, ventilatory approach, and selection of temporary mechanical circulatory support (tMCS). jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine

Assign a SCAI shock stage and document its trajectory. Stages range from A, at risk, to E, extremis; stages C through E identify overt hypoperfusion requiring intervention, treatment failure, or circulatory collapse. Serial staging is more informative than baseline staging alone. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

Look for hypoperfusion: altered mentation, cool or mottled extremities, oliguria, rising lactate, metabolic acidosis, worsening creatinine, or hepatic injury. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Assess congestion and ventricular phenotype: jugular venous pressure, pulmonary edema, peripheral edema, focused cardiac and lung ultrasound, and formal echocardiography. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology
Obtain early lactate and repeat it serially; the ACC guidance cited in the perfusion review supports arterial lactate monitoring every 1 to 4 hours. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Use arterial-line monitoring and consider early pulmonary artery catheterization when shock is established or phenotype, filling pressures, right ventricular function, or response to therapy is uncertain. ACC+1ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

Bedside SCAI shock features relevant to triage and escalation. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Stage	Operational clinical meaning	High-value findings
B: Beginning	Hemodynamic instability without clear hypoperfusion	SBP <90 mm Hg, MAP <60 mm Hg, or major decline from baseline; normal lactate in the consensus framework. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
C: Classic	Hypoperfusion requiring treatment beyond volume resuscitation	Lactate ≥2 mmol/L, renal or hepatic injury, hypotension requiring drugs or devices, or low cardiac output with elevated filling pressures. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
D: Deteriorating	Failure of initial therapy	Worsening perfusion despite initial treatment; need for multiple vasopressors or addition of MCS. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
E: Extremis	Refractory circulatory collapse	Cardiac arrest, ongoing CPR, profound hypotension despite maximal support, severe acidosis, or marked hyperlactatemia. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

Hemodynamic definition

Use multimodal monitoring to identify the limiting physiology

A normalizing MAP does not prove restoration of tissue perfusion.

Initial testing should identify the precipitant and quantify organ injury: CBC, comprehensive metabolic panel, lactate, arterial or venous blood gas, troponin, natriuretic peptides, ECG, chest radiography, and urgent echocardiography or point-of-care ultrasound. ACCACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology Echocardiography should assess LV and RV systolic function, regional wall-motion abnormalities, acute mitral regurgitation, ventricular septal defect, pericardial effusion, and major valvular disease.

Pulmonary artery catheterization can distinguish predominant LV, RV, biventricular, and vasodilatory components and guide selection or escalation of vasoactive drugs, diuresis, fluids, ventilation, and tMCS. Observational data associate complete invasive hemodynamic profiling with lower in-hospital mortality, but prospective trials have not established a mortality benefit from hemodynamic-guided resuscitation itself. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

Interpret macrocirculatory measures with perfusion markers. MAP, cardiac index, and venous oxygen saturation can improve while microcirculatory hypoperfusion persists. Serial lactate, urine output, renal and hepatic function, mentation, peripheral temperature, and capillary refill remain essential response measures. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

Calculate cardiac power output when cardiac output is available: CPO = MAP × cardiac output/451; low CPO is associated with mortality and supports concern for severe pump failure. jacc+1jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report jaccOptimal Perfusion Targets in Cardiogenic Shock
Assess RV dysfunction with right atrial pressure, pulmonary artery pulsatility index, right atrial pressure/pulmonary capillary wedge pressure ratio, and echocardiography; RV dysfunction is associated with higher mortality. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Do not treat ScvO2 and mixed venous oxygen saturation as interchangeable during shock; their relationship becomes unreliable with altered regional blood flow and low venous oxygen saturation. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
A falling or persistently elevated lactate after initial stabilization signals inadequate perfusion or impaired clearance and should prompt reassessment of diagnosis, hemodynamics, coronary flow, congestion, and support strategy. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

Perfusion-directed monitoring in cardiogenic shock. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology
Domain	Measure	Interpretation and action
Clinical	Mentation, extremity temperature and mottling, jugular venous pressure, pulmonary congestion, urine output	Persistent hypoperfusion or congestion despite acceptable pressure requires re-phenotyping and escalation of support or decongestion. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Metabolic	Lactate, bicarbonate, pH, creatinine, aminotransferases	Trend rather than single values; worsening lactate or metabolic acidosis indicates failed resuscitation until another explanation is established. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report
Hemodynamic	MAP, cardiac output/index, filling pressures, CPO, pulmonary artery pulsatility index, SvO2	Use to define LV, RV, biventricular, or mixed physiology and to guide vasoactive and device selection. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology
Imaging	Urgent echocardiography or point-of-care ultrasound	Identify ventricular failure, acute ischemic complications, severe valvular disease, tamponade, and congestion. ACCACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology

Stabilization

Restore perfusion while treating the cause

Support is a bridge to definitive therapy, recovery, advanced heart failure therapy, or an informed transition in goals of care.

Stabilize airway, oxygenation, and ventilation while avoiding unnecessary delays to definitive treatment. Positive-pressure ventilation can improve LV afterload in profound LV failure but may worsen preload-dependent RV failure; ventilatory settings therefore require phenotype-specific hemodynamic reassessment. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

In acute MI-associated shock, pursue urgent coronary angiography and culprit-vessel revascularization. Early revascularization is the treatment with established mortality benefit in this population. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock jaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction Concurrently identify mechanical complications and urgent surgical or structural-intervention needs.

Use vasoactive drugs as temporary support, titrated to arterial pressure and serial indicators of end-organ perfusion. A fixed MAP target is not evidence-based in cardiogenic shock. MAP ≥65 mm Hg is commonly used as an initial pragmatic target, but current guidance emphasizes individualized targets and serial perfusion assessment rather than pressure alone. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

Give fluids only when hypovolemia or preload responsiveness is plausible; indiscriminate fluid loading can worsen pulmonary edema and biventricular congestion. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine
Use diuresis or other decongestive therapy when congestion is prominent and perfusion can be maintained; elevated biventricular filling pressures are associated with higher mortality. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Correct reversible precipitants: acute coronary occlusion, unstable tachy- or bradyarrhythmia, mechanical complication, severe valve lesion, tamponade, pulmonary embolism, infection, bleeding, or medication-related decompensation. Wolters Kluwer+1Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology
Engage a multidisciplinary shock team early and arrange transfer when advanced invasive hemodynamics, tMCS, durable mechanical support, or transplant evaluation may be needed. ACC+1ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine

Vasoactive selection principles in cardiogenic shock. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock NEJMMilrinone as Compared with Dobutamine in the Treatment ...
Clinical problem	Preferred approach	Important limitation
Hypotension with inadequate perfusion pressure	Start norepinephrine and titrate to an individualized pressure and perfusion response. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock	No definitive cardiogenic-shock MAP target has been tested in randomized trials. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Persistent low output despite adequate pressure	Add an inotrope such as dobutamine or milrinone, selected by phenotype and safety considerations. NEJM+1NEJMMilrinone as Compared with Dobutamine in the Treatment ...jaccOptimal Perfusion Targets in Cardiogenic Shock	DOREMI found no clear outcome difference between milrinone and dobutamine. NEJMNEJMMilrinone as Compared with Dobutamine in the Treatment ...
Consideration of dopamine	Generally avoid as first-line vasopressor when norepinephrine is available. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock	Dopamine was associated with more arrhythmias and higher 28-day mortality in the cardiogenic-shock subgroup of SOAP II. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Consideration of epinephrine in acute MI-associated shock	Reserve for selected circumstances when alternatives are insufficient. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock	Small randomized data found more refractory shock and lactic acidosis versus norepinephrine. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

Vasoactive therapy

When hypotension and insufficient perfusion pressure require a vasopressor, norepinephrine is generally preferred. In the SOAP II cardiogenic-shock subgroup, dopamine was associated with more arrhythmias and higher 28-day mortality than norepinephrine. In the small OptimaCC trial of acute MI-associated shock, epinephrine was associated with more refractory shock and lactic acidosis than norepinephrine. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

Add an inotrope when impaired contractility and low output persist after adequate perfusion pressure is addressed. Dobutamine and milrinone are commonly used, but the DOREMI randomized trial found no significant difference between them in a composite clinical outcome. Agent choice should therefore be individualized to blood pressure, arrhythmia burden, renal function, beta-blocker exposure, pulmonary vascular/RV physiology, and local familiarity; source material does not provide validated dosing details for this setting. NEJM+1NEJMMilrinone as Compared with Dobutamine in the Treatment ...jaccOptimal Perfusion Targets in Cardiogenic Shock

Norepinephrine: preferred vasopressor when low blood pressure compromises organ perfusion; monitor for excessive afterload, ischemia, tachyarrhythmia, and peripheral ischemia. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Dobutamine or milrinone: consider for persistent low-output physiology; monitor rhythm, blood pressure, lactate trajectory, renal function, and vasopressor requirement. No randomized evidence establishes superiority of one over the other. NEJM+1NEJMMilrinone as Compared with Dobutamine in the Treatment ...jaccOptimal Perfusion Targets in Cardiogenic Shock
Avoid interpreting epinephrine-associated lactate elevation as necessarily improved or worsened perfusion without integrating the entire clinical and hemodynamic trajectory. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

Escalation

Escalate to temporary mechanical circulatory support selectively

Device selection requires a defined physiologic goal and an exit strategy.

Consider tMCS when end-organ perfusion cannot be maintained with pharmacologic therapy, when vasoactive requirements are escalating, or when a bridge is needed to myocardial recovery, definitive intervention, durable mechanical support, transplant, or diagnostic decision-making. The ACC guidance emphasizes invasive hemodynamic monitoring, continued reassessment, advanced-therapy candidacy, and transfer pathways. ACCACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology

Routine tMCS for all cardiogenic shock is not supported. A contemporary review notes that randomized trials had not shown survival benefit from routine tMCS, and the ECLS-SHOCK trial found no benefit from routine extracorporeal life support in infarct-related shock. Wolters Kluwer+1Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine NEJMExtracorporeal Life Support in Infarct-Related Cardiogenic ... Device use should therefore be individualized rather than driven by shock stage alone.

Choose support according to ventricular involvement, oxygenation requirement, congestion, vascular access, coronary and valvular anatomy, neurologic status, bleeding risk, anticipated duration, and whether the patient has a viable recovery or advanced-therapy pathway. Reassess for device-related bleeding, limb ischemia, stroke, hemolysis, infection, ventricular distension, and inadequate unloading or flow. Wolters Kluwer+1Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology

LV-predominant shock: consider an LV-unloading or forward-flow strategy when severe LV failure persists despite pharmacologic stabilization; selection depends on institutional capability and the intended bridge. Wolters Kluwer+1Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine ESCCardiogenic Shock and Acute Mechanical Circulatory Support
RV-predominant shock: avoid excessive preload reduction and high intrathoracic pressure; define RV failure using echocardiography and invasive hemodynamics before choosing support. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock
Biventricular failure or severe hypoxemia: extracorporeal support may provide systemic and respiratory support, but routine use in infarct-related shock has not improved survival. NEJM+1NEJMExtracorporeal Life Support in Infarct-Related Cardiogenic ...Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine
Before cannulation, document the exit strategy: recovery, revascularization or valve intervention, bridge to durable support or transplant, bridge to decision, or non-escalation based on prognosis and patient preferences. Wolters KluwerWolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine

When to reassess and escalate support. jacc+2jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine
Finding	Implication	Next action
Rising lactate, worsening acidosis, oliguria, altered mentation, or escalating vasoactive support	Persistent or worsening hypoperfusion	Repeat bedside imaging and hemodynamic assessment; address reversible cause and activate shock-team review for tMCS or transfer. ACC+1ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine
Progression from SCAI B or C within the first 24 hours	High-risk trajectory	Escalate monitoring and support rather than waiting for refractory shock. jaccjaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report
Persistent congestion with low output or suspected RV failure	Phenotype may be misclassified or incompletely treated	Use pulmonary artery catheter data and echocardiography to guide preload, afterload, inotrope, ventilator, and device decisions. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology
No viable bridge or irreversible multiorgan or neurologic injury	Potentially nonbeneficial escalation	Conduct structured goals-of-care discussion with patient or surrogate and multidisciplinary team. NEJM+1NEJMCardiogenic Shock Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine

Prognosis

Communicate prognosis using trajectory, phenotype, and patient reserve

Avoid prognostication from a single variable or a single early shock stage.

Mortality remains substantial. Contemporary reviews report short-term mortality exceeding 30%, and ACC communications cite an in-hospital mortality range of 30% to 50%. Wolters Kluwer+1Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology In a multicenter registry, unadjusted in-hospital mortality was highest for SCAI stage E at presentation, 59.6%, and was particularly high when patients progressed to stage E by 24 hours. jaccjaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

The first 24 hours are prognostically decisive. In a registry of 3,268 patients, more than one-half of patients initially classified as SCAI B or C worsened by 24 hours; patients with any stage worsening by 24 hours had 44.6% unadjusted in-hospital mortality. Lower lactate among survivors was a consistent discriminating feature in stages C through E. jaccjaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

For acute MI-associated shock, longer-term outcomes remain poor even among hospital survivors. In a population cohort, mortality was 40.9% at 1 year and 58.9% at 5 years; among hospital survivors, 47.5% were readmitted within 1 year and 42.0% required greater care support at discharge than before admission. These data are prognostic context, not a substitute for individualized assessment. jaccjaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction

Risk modifiers include worsening SCAI stage, elevated lactate, older age, organ dysfunction, frailty or preadmission dependency, and need for renal replacement therapy. jacc+1jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report jaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction
Use risk scores cautiously. A 2026 systematic review found no clearly superior model; CardShock had the highest pooled discrimination, but performance differences from several other scores were small. Wolters KluwerWolters KluwerPredictive Models for Mortality in Cardiogenic... : Critical Care Medicine
Discuss prognosis iteratively after initial stabilization, serial neurologic assessment when cardiac arrest occurred, response to revascularization or support, and clarification of the feasible exit strategy. jacc+1jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine

Trajectory-based prognostic information for discussions with families. jacc+1jaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report jaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction
Time point	Observed outcome	Clinical use
First 24 hours	Any SCAI-stage worsening was associated with 44.6% unadjusted in-hospital mortality in a multicenter registry. jaccjaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report	Treat worsening as a signal for urgent reassessment and escalation, not merely a prognostic label. jaccjaccSerial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report
Acute MI-associated shock hospitalization	30.2% died in hospital in a 9,789-patient population cohort. jaccjaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction	Frame early uncertainty while emphasizing the importance of definitive revascularization and organ-response trajectory. jacc+1jaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction jaccOptimal Perfusion Targets in Cardiogenic Shock
One year after acute MI-associated shock	40.9% overall mortality; among hospital survivors, 47.5% were readmitted within 1 year. jaccjaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction	Plan postdischarge heart-failure, ischemic, renal, functional, and rehabilitation follow-up before discharge. jaccjaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction

Common questions

Can cardiogenic shock be present without hypotension?

Yes. Hypoperfusion may occur with preserved blood pressure; assess lactate, urine output, mentation, skin perfusion, renal and hepatic injury, congestion, and hemodynamics rather than relying on blood pressure alone. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine

What is the preferred initial vasopressor in cardiogenic shock?

Norepinephrine is generally preferred when vasopressor support is needed for inadequate perfusion pressure. Dopamine was associated with more arrhythmias and higher 28-day mortality in the cardiogenic-shock subgroup of SOAP II, while epinephrine caused more refractory shock and lactic acidosis than norepinephrine in a small acute MI-shock trial. jaccjaccOptimal Perfusion Targets in Cardiogenic Shock

When should a pulmonary artery catheter be used?

Consider early pulmonary artery catheterization for established shock, uncertain phenotype, suspected RV or biventricular failure, persistent hypoperfusion, escalating vasoactive requirements, or tMCS decisions. ACC guidance supports invasive hemodynamic monitoring for diagnosis and management, although randomized outcome benefit remains unproven. ACC+1ACCAmerican College of Cardiology Issues Concise Clinical Guidance on Evaluation and Management of Cardiogenic Shock - American College of Cardiology jaccOptimal Perfusion Targets in Cardiogenic Shock

Does routine mechanical circulatory support improve survival?

No. Routine tMCS has not consistently improved survival in randomized studies, and routine extracorporeal life support did not improve outcomes in infarct-related shock. Use devices selectively for refractory hypoperfusion with a clear physiologic objective and exit strategy. Wolters Kluwer+1Wolters KluwerAdvances in the Management of Cardiogenic Shock : Critical Care Medicine NEJMExtracorporeal Life Support in Infarct-Related Cardiogenic ...

What is the most important definitive intervention in acute MI-associated cardiogenic shock?

Urgent culprit-vessel revascularization is the intervention with established mortality benefit in acute MI-associated cardiogenic shock. jacc+1jaccOptimal Perfusion Targets in Cardiogenic Shock jaccLong-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction